NIH's Clot-Busting Antibodies Free for Cancer-COVID License
Published Date: 8/12/2026
Notice
Summary
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
NCI Offering sTF Licensing Opportunity
The National Cancer Institute (NCI) is offering its soluble tissue factor (sTF) humanized monoclonal antibodies and related diagnostic and therapeutic methods for licensing or collaborative development. Partnership opportunities explicitly include preclinical optimization, clinical development, and diagnostic assay co-development.
Potentially More Accurate Thrombosis Test
The NCI describes soluble tissue factor (sTF) as offering a much more sensitive and specific test of thrombosis than the current D-dimer test. This discovery is presented as a basis for diagnostic tools such as ELISA and point-of-care assays for earlier detection and monitoring of thrombosis.
Safer Anti-Thrombosis Therapeutic Approach
NCI reports humanized monoclonal antibodies that selectively neutralize soluble tissue factor (sTF) can block pathological thrombosis without systemic anticoagulation and while preserving normal hemostasis. The notice describes in vivo validation showing prevention of fibrinogen depletion and normalization of coagulation parameters.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22871, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for eye disease, neuronal injury, infectious diseases, and related projects. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-22550, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding two closed virtual meetings on November 30, 2026, to review important grant applications. These meetings affect researchers applying for funding in cardiovascular sciences and tobacco regulatory science. No public access is allowed to protect private info and trade secrets, and the reviews help decide who gets research money.
2026-22558, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for health-related projects, ensuring privacy for sensitive information. No direct money changes are announced, but these reviews help decide who gets research grants.
2026-22339, Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human
The National Institutes of Health plans to give AntaraCore Systems, Inc. an exclusive license to use new catheter technology that treats dangerous heart rhythm problems called ventricular arrhythmia. This means AntaraCore will have special rights to develop and sell this life-saving treatment. If you want to comment or apply for a license, you must do so by December 2, 2026.
2026-22196, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a public meeting on May 12, 2027, to discuss important council business and review grant applications. People interested can attend in person or online, but space is limited and some parts of the meeting will be private to protect sensitive information. This meeting affects researchers and organizations seeking funding and sets the stage for future diabetes and kidney disease research support.
2026-22111, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a virtual meeting on June 4, 2027, to share updates and review grant applications and staff performance. The first half is open to the public, while the second half is private to protect personal privacy. This meeting affects researchers and staff involved with NICHD grants and projects, with no direct cost changes announced.
Previous / Next Documents
Previous: 2026-16439, Government Owned Invention Available for License: Quantitative Particle Identification (QPID) Digital Autoradiography System
The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a QPID digital autoradiography system with particle identification capabilities.
Next: 2026-16441, Government Owned Invention Available for License: DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification
The government has created a cool new tool that uses DNA patterns to help doctors classify cancer tumors more accurately, especially in the brain, kidney, and blood. This tech cuts down on guesswork and makes diagnoses clearer, helping patients get the right treatment faster. It’s ready for licensing now, so companies can bring this game-changing cancer test to clinics and labs soon.